ACM
FOLD

Allred Capital Management’s Amicus Therapeutics FOLD Stock Holding History

Allred Capital Management’s Portfolio FOLD Stock Details FOLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-500
Closed -$4.94K – 390
2021
Q1 		$4.94K Buy
+500
New +$7.74K ﹤0.01% 677
2020
Q1 		– Sell
-500
Closed -$4.87K – 336
2019
Q4 		$4.87K Buy
+500
New +$4.58K ﹤0.01% 663

Other funds holding FOLD

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Allred Capital Management's FOLD Position: Q2 2021 in Review

Allred Capital Management sold out of Amicus Therapeutics (FOLD) in Q2 2021, closing a stake of 500 shares — an estimated $4.94K sold.

Allred Capital Management first reported a position in FOLD in Q4 2019 and held it in 2 quarters. The position peaked at $4.94K in Q1 2021. 235 funds tracked by Wall St. Rank hold FOLD as of Q2 2021.

  • Allred Capital Management reported no remaining Amicus Therapeutics position as of Q2 2021 after selling out during the quarter.
  • Allred Capital Management sold 500 Amicus Therapeutics shares in Q2 2021, an estimated $4.94K.
  • Allred Capital Management first reported a position in Amicus Therapeutics in Q4 2019 and held it in 2 quarters.
  • Allred Capital Management's Amicus Therapeutics position peaked at $4.94K in Q1 2021.
  • 235 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q2 2021.

Based on Allred Capital Management's 13F filing for Q2 2021, filed 5 Aug 2021.